TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29687650

Group type: EXPERIMENTAL
Intervention: Weight loss plus whey protein supplementation (total protein: 1.2 g/kg/d)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Weight loss and the recommended daily allowance for protein (0.8 g/kg/d)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Weight maintenance (WM)
Number of subjects: 70
Study: 27050056

Group type: EXPERIMENTAL
Intervention: LYM‐X‐SORB (LXS)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 24941787

Group type: EXPERIMENTAL
Intervention: Ambulance equipped with ventilation
Number of subjects: 127

Group type: COMPARATOR
Intervention: No ventilator in ambulance (comparison group)
Number of subjects: 127
Study: 23095566

Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidopexy (SH)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Milligan-Morgan haemorrhoidectomy (MMH)
Number of subjects: 79
Study: 20185805

Group type: EXPERIMENTAL
Intervention: Anemic residents treated with at least one medication
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Anemic residents associated with chronic kidney disease
Number of subjects: 451

Group type: COMPARATOR
Intervention: Residents without anemia
Number of subjects: 451
Study: 18206569

Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC) exercises; specific dosage and duration not mentioned.
Number of subjects: 0
Study: 15923937

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional therapy
Number of subjects: 0
Study: 11121996

Group type: EXPERIMENTAL
Intervention: Sildenafil (25 mg, 50 mg, 100 mg)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 315
Study: 9772138

Group type: EXPERIMENTAL
Intervention: High-energy supplement (HES) 2.14 MJ/d
Number of subjects: 102

Group type: COMPARATOR
Intervention: Low-energy supplement (LES) 0.50 MJ/d
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: High-energy supplement (HES)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Low-energy supplement (LES)
Number of subjects: 102
Study: 7876659

Group type: EXPERIMENTAL
Intervention: Contrast echocardiography with 200 mg/ml and 400 mg/ml SHU 508A intravenously
Number of subjects: 20
Study: 3207375

Group type: EXPERIMENTAL
Intervention: Intravenous pulsed methylprednisolone
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Both groups (treated and control)
Number of subjects: 143
Study: 2227816

Group type: EXPERIMENTAL
Intervention: Selective intestinal decontamination with norfloxacin for 7 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (14 untreated patients)
Number of subjects: 14
Study: 1105833

Group type: EXPERIMENTAL
Intervention: Neomycin-erythromycin combination (3 gm of each, day preoperatively, plus mechanical cleansing)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Other preparations
Number of subjects: 97
Study: 31610826

Group type: EXPERIMENTAL
Intervention: Pasture only (P)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pasture plus 25% dietary DM intake as barley-based concentrate (PC25)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pasture plus 50% dietary DM intake as barley-based concentrate (PC50)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Barley-based concentrate ration (C)
Number of subjects: 48
Study: 30909761

Group type: EXPERIMENTAL
Intervention: Cysteamine cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 28081990

Group type: EXPERIMENTAL
Intervention: Standard volume local anesthetic administered (Group S, n=30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low volume anesthetic administered (Group L, n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups (Group L and Group S)
Number of subjects: 60
Study: 25599541

Group type: EXPERIMENTAL
Intervention: Iontophoresis-assisted transepithelial corneal collagen cross-linking (CXL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Iontophoresis-assisted transepithelial CXL
Number of subjects: 12
Study: 23649104

Group type: EXPERIMENTAL
Intervention: VascuLuminator
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control
Number of subjects: 88
Study: 21084721

Group type: EXPERIMENTAL
Intervention: Blue-green light delivered via cap visor in the morning
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dim red light delivered via cap visor in the morning
Number of subjects: 20
Study: 19708912

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 37
Study: 17276853

Group type: EXPERIMENTAL
Intervention: Xeno III self-etching adhesive with Transbond XT composite resin adhesive
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Xeno III self-etching adhesive with Fuji Ortho LC resin-modified glass ionomer cement
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional acid-etch conditioner with Transbond XT composite resin adhesive
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional acid-etch conditioner with Fuji Ortho LC resin-modified glass ionomer cement
Number of subjects: 120

Group type: COMPARATOR
Intervention: 10% polyacrylic acid with Transbond XT composite resin adhesive
Number of subjects: 120

Group type: COMPARATOR
Intervention: 10% polyacrylic acid with Fuji Ortho LC resin-modified glass ionomer cement
Number of subjects: 120
Study: 15507062

Group type: EXPERIMENTAL
Intervention: Relocated nursing home residents
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group residents (not yet moved)
Number of subjects: 77
Study: 11445475

Group type: EXPERIMENTAL
Intervention: Anterior vaginal wall suspension for urethral hypermobility (UH group)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Repair of grade 3 cystocele (C group)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (continent patients)
Number of subjects: 88
Study: 9722036

Group type: EXPERIMENTAL
Intervention: L-NAME 1 mg x kg(‐1) x h(‐1) for 12 hours
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 11
Study: 8064606

Group type: EXPERIMENTAL
Intervention: Alcon MZ20BD oval-optic PMMA IOL
Number of subjects: 182

Group type: COMPARATOR
Intervention: STAAR AQ1016 round-optic silicone IOL
Number of subjects: 182
Study: 3051839

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine (TS) adhesive, delivering 140 micrograms initially and 5 micrograms/h thereafter
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Droperidol (DHBP) 0.5 ml (1.25 mg) i.v.
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (0.5 ml i.v.)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine (TS)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Droperidol (DHBP)
Number of subjects: 96
Study: 31206301

Group type: COMPARATOR
Intervention: Thyroid Doppler ultrasonography (Thyroid volume, Resistance index (RI), and Pulsatility index (PI))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thyroid function tests
Number of subjects: 60

Group type: COMPARATOR
Intervention: Correlation analysis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Serum ferritin levels
Number of subjects: 60
Study: 28634136

Group type: EXPERIMENTAL
Intervention: Tongxie
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Pinaverium (50 mg tablets, 3 times daily for 4 weeks)
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1044
Study: 25773472

Group type: EXPERIMENTAL
Intervention: Cigarette smokers who concurrently use hookah (n = 270)
Number of subjects: 1217

Group type: COMPARATOR
Intervention: Non-hookah users (control group)
Number of subjects: 1217
Study: 23144445

Group type: EXPERIMENTAL
Intervention: Cindunistat 50 mg/day
Number of subjects: 1457

Group type: EXPERIMENTAL
Intervention: Cindunistat 200 mg/day
Number of subjects: 1457

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1457

Group type: EXPERIMENTAL
Intervention: Cindunistat (50 or 200 mg/day)
Number of subjects: 1457
Study: 21613554

Group type: EXPERIMENTAL
Intervention: Diet modification (n = 118)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Exercise (n = 117)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Diet + exercise (n = 117)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Control (n = 87)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Weight loss categories (<5%, 5-9.9%, 10-14.9%, ≥15%)
Number of subjects: 439
Study: 19951602

Group type: EXPERIMENTAL
Intervention: Intracoronary nitroprusside (group A)
Number of subjects: 92
Study: 16945898

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri ATCC 55730 via straw (200 ml of water through a prepared straw once daily for 3 weeks)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri ATCC 55730 via tablet (one tablet once daily for 3 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo straw (200 ml of water through a placebo straw once daily for 3 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo tablet (one placebo tablet once daily for 3 weeks)
Number of subjects: 120
Study: 14705152

Group type: EXPERIMENTAL
Intervention: Fluoxetine plus nutritional supplements
Number of subjects: 26

Group type: COMPARATOR
Intervention: Fluoxetine plus nutritional placebo
Number of subjects: 26
Study: 11318062

Group type: EXPERIMENTAL
Intervention: Beat-based timing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interval-based timing
Number of subjects: 0
Study: 9129014

Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF (0.3 to 5.0 microg/kg) with filgrastim (5 microg/kg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo with filgrastim (5 microg/kg)
Number of subjects: 41
Study: 8204245

Group type: EXPERIMENTAL
Intervention: Nicardipine 1 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Diltiazem 5 mg
Number of subjects: 26
Study: 3294914

Group type: EXPERIMENTAL
Intervention: Listerine mouthrinse (20 ml for 30 s, twice daily)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse (0.2% or 0.1% solution, 10 ml for 60 s, twice daily)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (20 ml mouthrinse for 30 s, twice daily)
Number of subjects: 96
Study: 30517725

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 3362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3362

Group type: EXPERIMENTAL
Intervention: Total MUFAs and total PUFAs
Number of subjects: 3362

Group type: EXPERIMENTAL
Intervention: n-6 PUFAs (ω-6 PUFAs)
Number of subjects: 3362
Study: 26869374

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Brachial plexus blockade
Number of subjects: 36
Study: 25476072

Group type: EXPERIMENTAL
Intervention: Outreach-based treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Institution-based services
Number of subjects: 46
Study: 22673369

Group type: EXPERIMENTAL
Intervention: Human multipotent cardiovascular progenitor cells generated from human iPS cells, followed by selective differentiation into cardiomyocytes (CMs), endothelial cells (ECs), and smooth muscle cells (SMCs).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiomyocytes purified from iPS cells derived from a patient with LEOPARD syndrome.
Number of subjects: 0
Study: 20207664

Group type: EXPERIMENTAL
Intervention: Treatment effects related to smoking cessation
Number of subjects: 3927

Group type: EXPERIMENTAL
Intervention: Treatment effects related to diet
Number of subjects: 3927

Group type: EXPERIMENTAL
Intervention: Treatment effects related to sun exposure
Number of subjects: 3927
Study: 17557319

Group type: EXPERIMENTAL
Intervention: 12-month primary care, phone and Internet-based behavioral intervention
Number of subjects: 401

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 401
Study: 16045061

Group type: EXPERIMENTAL
Intervention: Bright light (10,000 lux, n = 10)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High-density negative air ions (4.5 x 10(14) ions/s flow rate, n = 12)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low-density negative air ions (1.7 x 10(11) ions/s, n = 10, placebo control)
Number of subjects: 32
Study: 11828279

Group type: EXPERIMENTAL
Intervention: Leukocyte-depletion group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 10426235

Group type: EXPERIMENTAL
Intervention: Misoprostol 600 microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misoprostol 400 microg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular oxytocin 10 IU
Number of subjects: 0
Study: 7844605

Group type: COMPARATOR
Intervention: Pregnancy before diagnosis
Number of subjects: 2119

Group type: COMPARATOR
Intervention: Pregnancy during the 5-year period preceding breast cancer diagnosis
Number of subjects: 2119

Group type: COMPARATOR
Intervention: Pregnancy after breast cancer diagnosis
Number of subjects: 2119
Study: 2149051

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Ceftazidime + Teicoplanin
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin + Teicoplanin
Number of subjects: 86

Group type: COMPARATOR
Intervention: Ciprofloxacin (monotherapy)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Ceftazidime and Ciprofloxacin (comparison)
Number of subjects: 86
Study: 85053

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Metoprolol (50 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31761287

Group type: EXPERIMENTAL
Intervention: Nonintubated anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30991136

Group type: EXPERIMENTAL
Intervention: S. striata mouthwash
Number of subjects: 50

Group type: COMPARATOR
Intervention: Irsha mouthwash
Number of subjects: 50
Study: 28534225

Group type: EXPERIMENTAL
Intervention: Controlled dietary acrylamide intake via coffee (0.15-0.17 µg/kg bw) and a meal (14.1-15.9 µg/kg bw) on days 6 and 10 respectively.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Controlled dietary acrylamide minimized diet (0.05-0.06 µg/kg bw) throughout the 13-day study period.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ingestion of 13C3D3-AA (1 µg/kg bw) on day 6.
Number of subjects: 12
Study: 26824990

Group type: EXPERIMENTAL
Intervention: Probiotic treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 60
Study: 25400681

Group type: EXPERIMENTAL
Intervention: Vitamin D3 2000 IU once daily
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 22289783

Group type: EXPERIMENTAL
Intervention: After-school physical activity program (12 weeks, 24 sessions of aerobic exercise)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Control group (60 children without mothers)
Number of subjects: 470
Study: 20422150

Group type: EXPERIMENTAL
Intervention: Small dead space heat and moisture exchanger (HME)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Heated humidifier (HH)
Number of subjects: 50
Study: 17940860

Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride, 0.4 mg/kg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride
Number of subjects: 56
Study: 15878004

Group type: EXPERIMENTAL
Intervention: Rhythm control (Cardioversion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rate control (Atrioventricular junctional ablation)
Number of subjects: 0
Study: 12437389

Group type: EXPERIMENTAL
Intervention: Letter and telephone recall for PCV7 vaccination (intervention group)
Number of subjects: 1234

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 1234
Study: 10613225

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO), 6000 U i.v. twice weekly for 3 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 37
Study: 7484202

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 21
Study: 1366265

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 39
Study: 3888836

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg b.i.d.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30113664

Group type: EXPERIMENTAL
Intervention: Collar use
Number of subjects: 35

Group type: COMPARATOR
Intervention: No collar use
Number of subjects: 35
Study: 29153938

Group type: EXPERIMENTAL
Intervention: Tribendimidine (200 mg for children, 400 mg for adolescents and adults)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Praziquantel (50 mg/kg bodyweight and 25 mg/kg bodyweight, 6 h apart)
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Tribendimidine
Number of subjects: 607

Group type: COMPARATOR
Intervention: Praziquantel
Number of subjects: 607
Study: 26768923

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O) 65% in oxygen (O2) via mask, flow of 10 L/min
Number of subjects: 15

Group type: COMPARATOR
Intervention: Oxygen (O2) only, flow of 10 L/min (control group)
Number of subjects: 15
Study: 24566240

Group type: EXPERIMENTAL
Intervention: Adult day service (ADS) use
Number of subjects: 151

Group type: COMPARATOR
Intervention: Nonintervention days
Number of subjects: 151
Study: 24246407

Group type: EXPERIMENTAL
Intervention: LY2181308 plus docetaxel/prednisone
Number of subjects: 154

Group type: COMPARATOR
Intervention: Standard first-line docetaxel/prednisone (control arm)
Number of subjects: 154
Study: 22124042

Group type: EXPERIMENTAL
Intervention: PRP + bone graft (HA + β TCP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: saline + bone graft (HA + β TCP)
Number of subjects: 10
Study: 19127416

Group type: EXPERIMENTAL
Intervention: Hepatitis B lay health worker intervention
Number of subjects: 460

Group type: COMPARATOR
Intervention: Direct mailing of physical activity educational materials (Control)
Number of subjects: 460
Study: 17431082

Group type: EXPERIMENTAL
Intervention: Normoxic (21% Fi(O2))
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Acute hypoxic (12% Fi(O2))
Number of subjects: 13

Group type: COMPARATOR
Intervention: Both Norm and Hypox
Number of subjects: 13
Study: 15389231

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day) plus atorvastatin (10 mg/day, titrated to 40 mg/day if needed)
Number of subjects: 621

Group type: COMPARATOR
Intervention: Atorvastatin (10 mg/day, titrated to 80 mg/day if needed)
Number of subjects: 621

Group type: COMPARATOR
Intervention: Atorvastatin (20 mg/day)
Number of subjects: 621
Study: 11354527

Group type: EXPERIMENTAL
Intervention: CHO beverage (5% w/v)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PLA) beverage
Number of subjects: 9
Study: 9519951

Group type: EXPERIMENTAL
Intervention: Immediate regional node dissection
Number of subjects: 240

Group type: COMPARATOR
Intervention: Delayed regional node dissection
Number of subjects: 240

Group type: COMPARATOR
Intervention: Delayed regional node dissection in patients with occult regional node metastases
Number of subjects: 240

Group type: COMPARATOR
Intervention: Delayed regional node dissection in patients with regional node metastases
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Routine use of immediate node dissection
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Status of regional nodes
Number of subjects: 240
Study: 7722120

Group type: EXPERIMENTAL
Intervention: Candoxatrilat 200 mg
Number of subjects: 12
Study: 2024791

Group type: EXPERIMENTAL
Intervention: Metaproterenol (15 mg by nebulizer)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Atropine (1.5 mg by nebulizer)
Number of subjects: 40
Study: 7263931

Group type: EXPERIMENTAL
Intervention: Buprenorphine (Temgesic)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 98
Study: 31098430

Group type: EXPERIMENTAL
Intervention: Friction underwear
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-friction underwear
Number of subjects: 56
Study: 28138341

Group type: EXPERIMENTAL
Intervention: Foot orthoses
Number of subjects: 220

Group type: COMPARATOR
Intervention: Progressive resisted hip exercises
Number of subjects: 220
Study: 25664602

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg twice a day
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 23388208

Group type: EXPERIMENTAL
Intervention: Whole-grain foods during the 16-week intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no whole-grain foods during the intervention)
Number of subjects: 0
Study: 21776571

Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study: 19462694

Group type: EXPERIMENTAL
Intervention: Quality of life measured with the Kansas City Cardiomyopathy Quality of Life questionnaire (KCCQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depression measured with the Geriatric Depression Scale (GDS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive function measured with the Mini Mental State Examination (MMSE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurses' independent evaluation of QDF variables
Number of subjects: 0
Study: 17571092

Group type: EXPERIMENTAL
Intervention: Domiciliary denture service (complete dentures fitted immediately)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (treatment deferred to normal waiting list, received three home visits)
Number of subjects: 133
Study: 15519028

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg, equivalent to 2 cups of coffee)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Smoking (one cigarette)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Smoking followed by caffeine intake
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Chronic coffee consumption and smoking
Number of subjects: 184
Study: 11763244

Group type: EXPERIMENTAL
Intervention: OQLQ
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: QUALEFFO
Number of subjects: 338

Group type: COMPARATOR
Intervention: SF-36 and EQ-5D
Number of subjects: 338